Qihan Biotech is a biotechnology company applying genome-editing technology to develop novel cell therapies and organs for transplantation. The company’s mission is to use high-throughput, multiplexable genome editing in combination with expertise in transplantation immunology to create immunologically privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure, and other important medical conditions. With a vision to create a world in which cell and organ therapies are universally available to patients, Qihan Biotech has raised three rounds of financing and is advancing its cell therapy programs into IND-enabling investigations.
Company Details
- Employees
- 11
- Founded
- -
- Address
- Xiaoshan Science And Technology Park, Hangzhou,china
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.qihanbio.com/
- HQ
- Hangzhou
Qihan Biotechnology Co., Ltd. Questions
Qihan Biotechnology Co., Ltd.'s website is https://www.qihanbio.com/
Qihan Biotechnology Co., Ltd.'s LinkedIn profile is https://cn.linkedin.com/company/qihanbio
Qihan Biotechnology Co., Ltd. has
11 employees.
View email and phone details for 11
employees at Qihan Biotechnology Co., Ltd..
Qihan Biotechnology Co., Ltd.'s industry is
Biotechnology Research
Qihan Biotechnology Co., Ltd.'s top competitors are
Poseida Therapeutics, Inc.,
Starna Therapeutics,
Sundia Meditech Co., Ltd.,
Genemedi Biotech,
Alpha Biopharma,
Egenesis, Inc.,
Neukio Biotherapeutics,
杭州启函生物科技有限公司,
Meta Pharmaceuticals Inc.,
克睿基因 Cure Genetics.
Qihan Biotechnology Co., Ltd.'s categories are Biotechnology Research
Qihan Biotechnology Co., Ltd.'s founding year is 2017
